XCancer
Clarity Pharmaceuticals

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Description:

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Sponsor:

Clarity Pharmaceuticals

Phase:

Phase 3

Contacts:

Clarity Pharmaceuticals Clarity Clinical Trials Contact

clinicaltrials@claritypharmaceuticals.com

+61 (0) 2 9209 4037

Government Study Link:

NCT06970847 - Click here to see study on

ClinicalTrials.gov

64Cu-SAR-bisPSMA

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: SAR

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...